Total Payments
$251,647
2024 Payments
$110.47
Companies
14
Transactions
423
Medicare Patients
3,173
Medicare Billing
$3.1M
Payment Breakdown by Category
Other$175,134 (69.6%)
Travel$33,405 (13.3%)
Consulting$32,132 (12.8%)
Food & Beverage$10,940 (4.3%)
Education$37.05 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $172,434 | 82 | 68.5% |
| Travel and Lodging | $33,405 | 93 | 13.3% |
| Consulting Fee | $32,132 | 18 | 12.8% |
| Food and Beverage | $10,940 | 224 | 4.3% |
| Honoraria | $2,700 | 1 | 1.1% |
| Education | $37.05 | 5 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $100,863 | 130 | $0 (2019) |
| Amgen Inc. | $56,656 | 97 | $0 (2024) |
| AbbVie Inc. | $45,523 | 105 | $0 (2020) |
| Regeneron Healthcare Solutions, Inc. | $19,616 | 30 | $0 (2019) |
| Ironwood Pharmaceuticals, Inc | $13,514 | 17 | $0 (2018) |
| Regeneron Pharmaceuticals, Inc. | $5,892 | 12 | $0 (2020) |
| GENZYME CORPORATION | $5,071 | 11 | $0 (2021) |
| Horizon Therapeutics plc | $2,910 | 5 | $0 (2020) |
| Janssen Biotech, Inc. | $1,250 | 1 | $0 (2019) |
| Hikma Pharmaceuticals USA | $185.67 | 10 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $110.47 | 1 | Amgen Inc. ($110.47) |
| 2023 | $125.00 | 1 | AstraZeneca Pharmaceuticals LP ($125.00) |
| 2021 | $4,388 | 3 | Amgen Inc. ($3,544) |
| 2020 | $36,195 | 44 | Amgen Inc. ($28,112) |
| 2019 | $97,727 | 161 | Celgene Corporation ($44,873) |
| 2018 | $66,347 | 112 | Celgene Corporation ($31,584) |
| 2017 | $46,755 | 101 | Celgene Corporation ($24,406) |
All Payment Transactions
423 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/26/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $110.47 | General |
| Category: Inflammation | ||||||
| 06/20/2023 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 04/14/2021 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,025.00 | General |
| Category: Inflammation | ||||||
| 04/14/2021 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,518.75 | General |
| Category: Inflammation | ||||||
| 02/11/2021 | GENZYME CORPORATION | KEVZARA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $844.00 | General |
| Category: Rheumatology | ||||||
| 10/26/2020 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $810.00 | General |
| Category: Inflammation | ||||||
| 09/21/2020 | AbbVie Inc. | RINVOQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 03/12/2020 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,633.00 | General |
| Category: Inflammation | ||||||
| 03/10/2020 | AbbVie Inc. | RINVOQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: IMMUNOLOGY | ||||||
| 03/06/2020 | GENZYME CORPORATION | KEVZARA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $388.00 | General |
| Category: Immunology | ||||||
| 03/05/2020 | AbbVie Inc. | RINVOQ (Drug) | Food and Beverage | In-kind items and services | $88.00 | General |
| Category: IMMUNOLOGY | ||||||
| 02/29/2020 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,038.00 | General |
| Category: Inflammation | ||||||
| 02/29/2020 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $686.80 | General |
| Category: Inflammation | ||||||
| 02/29/2020 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $647.15 | General |
| Category: Inflammation | ||||||
| 02/29/2020 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $628.98 | General |
| Category: Inflammation | ||||||
| 02/29/2020 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Inflammation | ||||||
| 02/29/2020 | Amgen Inc. | Otezla (Drug) | Food and Beverage | Cash or cash equivalent | $104.03 | General |
| Category: Inflammation | ||||||
| 02/29/2020 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $90.56 | General |
| Category: Inflammation | ||||||
| 02/29/2020 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Inflammation | ||||||
| 02/29/2020 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $37.68 | General |
| Category: Inflammation | ||||||
| 02/28/2020 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,633.00 | General |
| Category: Inflammation | ||||||
| 02/28/2020 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $11.77 | General |
| Category: Inflammation | ||||||
| 02/27/2020 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,633.00 | General |
| Category: Inflammation | ||||||
| 02/27/2020 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $718.40 | General |
| Category: Inflammation | ||||||
| 02/27/2020 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $213.81 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 398 | 9,238 | $375,210 | $182,663 |
| 2022 | 17 | 804 | 63,281 | $2.7M | $785,156 |
| 2021 | 16 | 1,000 | 72,936 | $3.7M | $1.1M |
| 2020 | 14 | 971 | 37,755 | $3.4M | $1.0M |
Total Patients
3,173
Total Services
183,210
Medicare Billing
$3.1M
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 88 | 8,820 | $299,880 | $161,119 | 53.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 97 | 138 | $27,048 | $10,046 | 37.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 43 | 51 | $11,628 | $5,179 | 44.5% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 66 | 66 | $18,150 | $2,594 | 14.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $3,750 | $2,022 | 53.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 89 | 148 | $14,754 | $1,703 | 11.5% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 12 | 6,025 | $542,250 | $210,291 | 38.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 101 | 10,680 | $363,120 | $180,737 | 49.8% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2022 | 13 | 36,354 | $436,248 | $165,791 | 38.0% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 13 | 6,415 | $461,880 | $77,583 | 16.8% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 16 | 1,912 | $510,504 | $56,371 | 11.0% |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 2022 | 13 | 678 | $153,906 | $27,429 | 17.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 190 | 321 | $62,916 | $22,745 | 36.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 143 | 190 | $43,320 | $16,427 | 37.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 50 | 199 | $44,775 | $10,092 | 22.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 27 | 73 | $23,360 | $7,594 | 32.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 107 | 227 | $20,492 | $2,665 | 13.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 17 | 17 | $4,250 | $2,099 | 49.4% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 47 | 47 | $12,925 | $1,836 | 14.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 19 | 63 | $7,875 | $1,472 | 18.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 14 | 14 | $3,150 | $1,117 | 35.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 11 | 11 | $2,156 | $671.84 | 31.2% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2022 | 11 | 55 | $11,440 | $236.71 | 2.1% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2021 | 14 | 8,150 | $733,500 | $348,687 | 47.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 102 | 10,380 | $352,920 | $168,433 | 47.7% |
About J Toder
J Toder is a Rheumatology healthcare provider based in Johnston, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639249956.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, J Toder has received a total of $251,647 in payments from pharmaceutical and medical device companies, with $110.47 received in 2024. These payments were reported across 423 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($172,434).
As a Medicare-enrolled provider, Toder has provided services to 3,173 Medicare beneficiaries, totaling 183,210 services with total Medicare billing of $3.1M. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Johnston, RI
- Active Since 11/08/2006
- Last Updated 12/03/2007
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1639249956
Products in Payments
- Otezla (Drug) $132,384
- Otezla (Biological) $18,351
- KEVZARA (Biological) $16,615
- DUZALLO (Drug) $13,514
- KEVZARA SARILUMAB INJECTION (Biological) $10,125
- Humira (Biological) $9,433
- Rinvoq (Biological) $8,874
- KEVZARA (Drug) $3,839
- KRYSTEXXA (Biological) $2,910
- RINVOQ (Drug) $2,506
- SIMPONI ARIA (Biological) $1,250
- Enbrel (Biological) $314.06
- Mitigare (Drug) $185.67
- EVENITY (Biological) $136.50
- SAPHNELO (Biological) $125.00
- Prolia (Biological) $113.44
- TAVNEOS (Drug) $110.47
- Rituxan (Biological) $25.98
- FORTEO (Drug) $12.58
- SYNVISC-ONE (Device) $4.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.